tetano
Editor, Senior Moderator
Arterioscler Thromb Vasc Biol
. 2021 Feb 1;ATVBAHA120315551.
doi: 10.1161/ATVBAHA.120.315551. Online ahead of print.
Beneficial Effect of Statins in COVID-19-Related Outcomes: A National Population-Based Cohort Study
Hae-Young Lee[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Juhee Ahn[SUP] #[/SUP][SUP] 4 [/SUP], Juhong Park[SUP] 4 [/SUP], Chang Kyung Kang[SUP] 3 [/SUP], Sung-Ho Won[SUP] 4 5 [/SUP], Dong Wook Kim[SUP] 6 [/SUP], Jong-Heon Park[SUP] 6 7 [/SUP], Ki-Hyun Chung[SUP] 8 9 [/SUP], Joon-Sung Joh[SUP] 8 [/SUP], Jiwhan Bang[SUP] 10 9 [/SUP], Cheong Hee Kang[SUP] 6 [/SUP], Wook Bum Pyun[SUP] 1 [/SUP], Myoung-Don Oh[SUP] 2 3 9 [/SUP]
Affiliations
Abstract
Objective: Although statins are widely prescribed lipid-lowering drugs, there are concerns about the safety of their use in the context of coronavirus disease 2019 (COVID-19), since statins increase the expression of ACE2. This study aimed to disclose the association between statins and 60-day COVID-19 mortality. Approach and Results: All patients hospitalized with laboratory-confirmed COVID-19 were enrolled in this study from January 19 to April 16, 2020, in Korea. We evaluated the association between the use of statins and COVID-19-related mortality in the overall and the nested 1:2 propensity score-matched study. Furthermore, a comparison of the hazard ratio for death was performed between COVID-19 patients and a retrospective cohort of patients hospitalized with pneumonia between January and June 2019 in Korea. The median age of the 10 448 COVID-19 patients was 45 years. Statins were prescribed in 533 (5.1%) patients. After adjusting for age, sex, and comorbidities, Cox regression showed a significant decrease in hazard ratio associated with the use of statins (hazard ratio, 0.637 [95% CI, 0.425-0.953]; P=0.0283). Moreover, on comparing the hazard ratio between COVID-19 patients and the retrospective cohort of hospitalized pneumonia patients, the use of statins showed similar benefits.
Conclusions: The use of statins correlates significantly with lower mortality in patients with COVID-19, consistent with the findings in patients with pneumonia.
Keywords: COVID-19; cohort studies; hydroxymethylglutaryl-CoA reductase inhibitors; mortality; propensity score.
. 2021 Feb 1;ATVBAHA120315551.
doi: 10.1161/ATVBAHA.120.315551. Online ahead of print.
Beneficial Effect of Statins in COVID-19-Related Outcomes: A National Population-Based Cohort Study
Hae-Young Lee[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Juhee Ahn[SUP] #[/SUP][SUP] 4 [/SUP], Juhong Park[SUP] 4 [/SUP], Chang Kyung Kang[SUP] 3 [/SUP], Sung-Ho Won[SUP] 4 5 [/SUP], Dong Wook Kim[SUP] 6 [/SUP], Jong-Heon Park[SUP] 6 7 [/SUP], Ki-Hyun Chung[SUP] 8 9 [/SUP], Joon-Sung Joh[SUP] 8 [/SUP], Jiwhan Bang[SUP] 10 9 [/SUP], Cheong Hee Kang[SUP] 6 [/SUP], Wook Bum Pyun[SUP] 1 [/SUP], Myoung-Don Oh[SUP] 2 3 9 [/SUP]
Affiliations
- PMID: 33535790
- DOI: 10.1161/ATVBAHA.120.315551
Abstract
Objective: Although statins are widely prescribed lipid-lowering drugs, there are concerns about the safety of their use in the context of coronavirus disease 2019 (COVID-19), since statins increase the expression of ACE2. This study aimed to disclose the association between statins and 60-day COVID-19 mortality. Approach and Results: All patients hospitalized with laboratory-confirmed COVID-19 were enrolled in this study from January 19 to April 16, 2020, in Korea. We evaluated the association between the use of statins and COVID-19-related mortality in the overall and the nested 1:2 propensity score-matched study. Furthermore, a comparison of the hazard ratio for death was performed between COVID-19 patients and a retrospective cohort of patients hospitalized with pneumonia between January and June 2019 in Korea. The median age of the 10 448 COVID-19 patients was 45 years. Statins were prescribed in 533 (5.1%) patients. After adjusting for age, sex, and comorbidities, Cox regression showed a significant decrease in hazard ratio associated with the use of statins (hazard ratio, 0.637 [95% CI, 0.425-0.953]; P=0.0283). Moreover, on comparing the hazard ratio between COVID-19 patients and the retrospective cohort of hospitalized pneumonia patients, the use of statins showed similar benefits.
Conclusions: The use of statins correlates significantly with lower mortality in patients with COVID-19, consistent with the findings in patients with pneumonia.
Keywords: COVID-19; cohort studies; hydroxymethylglutaryl-CoA reductase inhibitors; mortality; propensity score.